GHRS Stock — GH Research PLC: Cash, EV, Pipeline

Share price

$28.26

Market cap

$1,937.4M

Cash

$357.5M

Enterprise value

$1,579.9M

Balance sheet

Cash	$357.5M
Debt	$0.0M
Net cash	$357.5M
Enterprise value	$1,579.9M
Basic shares	68.6M shares
Fully diluted shares	62.0M shares
Fully diluted market cap	$1,753.0M
Cash per share	$5.21

Cash figures as of 2026-05-14. Database snapshot: 2026-09-21.

Price history

Loading GHRS daily closes…

Loading price history…

Pipeline assets

GH001

Stage not disclosed · Active

Target serotonin receptor

Indications

Initial and additional indications (not named in excerpts) (Stage not disclosed)

Status note Lead candidate; delivered via proprietary aerosol delivery device; excerpts state no clinical stage or indications.

GH002

Stage not disclosed · Active

Target serotonin receptor

Indications

Initial and additional indications (not named in excerpts) (Stage not disclosed)

Status note Second candidate; excerpts state no clinical stage, modality or indications.

Per-asset detail extracted from the 20-F filed 2026-03-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	5,933,815	no change	1.36%	2026-08-14
Braidwell LP	207,240	+207,240	0.21%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

GHRS — GH Research PLC

Balance sheet

Price history

Pipeline assets

Institutional holders